4Aivazis V, Hatzimichail A, Papachristou A, et al. Clinical evaluation and changes of the respiratory epithelium function after administration of Pidotimod in Greek children with recurrent respiratory tract infections [J]. Minerva Pediatr, 2002, 54(4): 315
5Benetti GP, Fugazza L, Stramba Badiale M, et al. Ex vivo evaluation of pidotimod activity on cell-mediated immunity [J].Arzneimittelforschung, 1994, 44(12A): 1476.
6Migliorati G, Coppi G, D'Adamio F, et al. Immunopharmacology of Pidotimod: effect on natural killer cell activity and thymocyte cell death [J]. Pharmacol Res, 1992, 26 (Suppl 2): 154.
7Passali D, Calearo C, Conticello S. Pidotimod in the management of recurrent pharyngotonsillar infections in childhood[J]. Arzneimittelforschung, 1994, 44(12A): 1511.
8Delespesse G, Yang LP, Ohshima Y, et al. Maturation of human neonatal CD4+ and CD8+ T lymphocytes into Th1/Th2 effectors [J]. Vaccine, 1998, 16(14-15): 1415.
9Capsoni F, Minonzio F, Ongari AM, et al. Evaluation of the kinetics of the immunomodulating activity of Pidotimod on human neutrophils [J]. Pharmacol Res, 1992, 26 (Suppl 2): 172.
